[go: up one dir, main page]

BR9713690B1 - agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano. - Google Patents

agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano.

Info

Publication number
BR9713690B1
BR9713690B1 BRPI9713690-5A BR9713690A BR9713690B1 BR 9713690 B1 BR9713690 B1 BR 9713690B1 BR 9713690 A BR9713690 A BR 9713690A BR 9713690 B1 BR9713690 B1 BR 9713690B1
Authority
BR
Brazil
Prior art keywords
benzodioxane
benzodioxole
dihydrobenzofuran
benzofuran
melatoninergic
Prior art date
Application number
BRPI9713690-5A
Other languages
English (en)
Other versions
BR9713690A (pt
Inventor
Jonh D Catt
Graham Johnson
Daniel J Keavy
Ronald J Mattson
Michael F Parker
Katherine S Takaki
Joseph P Yevich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9713690A publication Critical patent/BR9713690A/pt
Publication of BR9713690B1 publication Critical patent/BR9713690B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18Ethylenedioxybenzenes, not substituted on the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D321/00Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02Seven-membered rings
    • C07D321/10Seven-membered rings condensed with carbocyclic rings or ring systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI9713690-5A 1996-12-10 1997-12-09 agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano. BR9713690B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3268996P 1996-12-10 1996-12-10
PCT/US1997/022627 WO1998025606A1 (en) 1996-12-10 1997-12-09 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents

Publications (2)

Publication Number Publication Date
BR9713690A BR9713690A (pt) 2000-05-02
BR9713690B1 true BR9713690B1 (pt) 2009-08-11

Family

ID=21866306

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713690-5A BR9713690B1 (pt) 1996-12-10 1997-12-09 agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano.

Country Status (25)

Country Link
US (3) US5856529A (pt)
EP (1) EP1027043B1 (pt)
JP (1) JP4290765B2 (pt)
KR (1) KR100499106B1 (pt)
CN (1) CN1152679C (pt)
AR (1) AR010346A1 (pt)
AT (1) ATE281833T1 (pt)
AU (1) AU719994B2 (pt)
BR (1) BR9713690B1 (pt)
CA (1) CA2274183C (pt)
CY (1) CY2501B1 (pt)
CZ (1) CZ297673B6 (pt)
DE (1) DE69731562T2 (pt)
DK (1) DK1027043T3 (pt)
ES (1) ES2230626T3 (pt)
HU (1) HU226524B1 (pt)
IL (1) IL129999A (pt)
NO (1) NO321450B1 (pt)
NZ (1) NZ335910A (pt)
PL (1) PL190499B1 (pt)
PT (1) PT1027043E (pt)
RU (1) RU2190609C2 (pt)
TW (1) TW476758B (pt)
WO (1) WO1998025606A1 (pt)
ZA (1) ZA9711051B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614347D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
CA2334299A1 (en) * 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
AU763963B2 (en) * 1999-06-30 2003-08-07 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
ATE327753T1 (de) 2001-05-15 2006-06-15 Hoffmann La Roche Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
JP2005505586A (ja) * 2001-10-04 2005-02-24 ワイス 5−ヒドロキシトリプタミン−6リガンドとしてのクロマン誘導体
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
RU2295520C2 (ru) * 2002-07-03 2007-03-20 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ОКСАЗОЛА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ СЕНСИБИЛИЗАТОРОВ ИНСУЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВИРУЮЩИМ ДЕЙСТВИЕМ В ОТНОШЕНИИ PRARα И/ИЛИ PRARγ
EP1537091B1 (en) * 2002-08-30 2010-10-06 F. Hoffmann-La Roche AG Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists
JP4286782B2 (ja) * 2002-09-12 2009-07-01 エフ.ホフマン−ラ ロシュ アーゲー 糖尿病の治療に有用な、pparアゴニストとしてのn−置換−1h−インドール−5−プロピオン酸化合物
RU2315767C2 (ru) * 2002-11-25 2008-01-27 Ф.Хоффманн-Ля Рош Аг Индолилпроизводные, способ их получения, фармацевтическая композиция, способ лечения и/или профилактики заболеваний
US7015831B2 (en) * 2002-12-17 2006-03-21 Evolution Robotics, Inc. Systems and methods for incrementally updating a pose of a mobile device calculated by visual simultaneous localization and mapping techniques
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
RU2445973C2 (ru) * 2006-05-22 2012-03-27 Ванда Фармасьютиклз, Инк. Способ лечения глубокой депрессии у человека
MX2008014841A (es) * 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de agonista de melatonina.
EP2141150B1 (en) * 2007-04-26 2013-12-11 Takeda Pharmaceutical Company Limited Bicyclic compound and pharmaceutical use thereof
US7964430B2 (en) * 2007-05-23 2011-06-21 Applied Materials, Inc. Silicon layer on a laser transparent conductive oxide layer suitable for use in solar cell applications
US11060144B2 (en) * 2007-09-13 2021-07-13 Vanda Pharmaceuticals Inc. Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP2287159A1 (en) * 2009-07-29 2011-02-23 V.Mane Fils New bicyclic dioxanes, their preparation and their use as organoleptic compounds
JP4944286B1 (ja) * 2010-09-22 2012-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 シクロプロパン化合物
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP4502609A3 (en) 2012-01-26 2025-04-09 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
MX2014014010A (es) * 2012-05-18 2015-02-12 Vanda Pharmaceuticals Inc Metabolitos de (1r-trans) -n - [[2- (2,3-dihidro-4-benzofuranilo) ciclopropilo] metilo] propanamida.
JPWO2014010603A1 (ja) 2012-07-10 2016-06-23 アステラス製薬株式会社 腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物、及び該医薬組成物に含有される化合物のスクリーニング方法
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
CN110200958A (zh) 2012-12-18 2019-09-06 万达制药公司 昼夜节律紊乱的治疗
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
US9573921B2 (en) * 2013-09-30 2017-02-21 Polfarmex S.A. Substituted N, N-dimethylaminoalkyl ethers of isoflavanone oximes as H1-receptor antagonists
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US12304896B2 (en) 2014-12-04 2025-05-20 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon
US10071977B2 (en) 2014-02-12 2018-09-11 Vanda Pharmaceuticals Inc. Highly purifid pharmaceutical grade tasimelteon
HRP20230070T1 (hr) 2014-09-02 2023-03-17 Vanda Pharmaceuticals Inc. Tasimelteon za liječenje smith-magenis sindroma
CN104327022B (zh) * 2014-10-17 2015-12-02 苏州明锐医药科技有限公司 他司美琼的制备方法
CN104402849B (zh) * 2014-11-11 2016-11-09 苏州莱克施德药业有限公司 他司美琼中间体的新制备工艺
CN106588841B (zh) * 2015-10-19 2019-01-25 富乐马鸿凯(大连)医药有限公司 合成2,3-二氢-1-苯并呋喃-4-甲醛的方法
KR20190008265A (ko) 2016-05-06 2019-01-23 피지션즈 씰, 엘엘씨 발레리안 조성물 및 관련 방법
CN105949153B (zh) * 2016-05-10 2018-03-02 浙江工业大学 一种他司美琼的合成方法
CN107365288A (zh) * 2016-05-12 2017-11-21 浙江京新药业股份有限公司 他司美琼的晶型
US9944616B2 (en) 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
CN106543119B (zh) * 2016-09-22 2019-07-26 浙江工业大学 一种光学纯他司美琼的制备方法
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
WO2018149940A1 (en) 2017-02-17 2018-08-23 Quimica Sintetica, S. A. Process for the preparation of enantiomerically enriched dihydrobenzofurans and intermediate compounds obtained in the process
US20210059973A1 (en) 2017-08-02 2021-03-04 Vanda Pharmaceuticals Inc. Treatment of Affective Disorders
WO2019173180A1 (en) * 2018-03-04 2019-09-12 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
CN113365618A (zh) * 2018-09-12 2021-09-07 万带兰制药公司 改善睡眠或睡醒后表现
MX2021012833A (es) 2019-05-15 2021-11-25 Eisai R&D Man Co Ltd Metodo y compuesto utiles en la preparacion del antagonista del receptor de orexina-2 y lemborexant que tiene pocas impurezas.
WO2021003086A1 (en) 2019-06-29 2021-01-07 Vanda Pharmaceuticals Inc. Tasimelteon use in treating sleep aberrations
MX2022006577A (es) * 2019-12-13 2022-07-04 Vanda Pharmaceuticals Inc Formulaciones liquidas de tasimelteon y metodos para su uso.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2667316B1 (fr) * 1990-10-02 1994-09-16 Roussel Uclaf Nouveaux derives du benzofuranne, leur procede de preparation et leur application comme pesticides.
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
CA2176854A1 (en) * 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
PT901483E (pt) * 1996-05-14 2003-11-28 Glaxo Group Ltd Benzofuranos e benzopiranos como agentes cronobiologicos

Also Published As

Publication number Publication date
NO992804L (no) 1999-08-09
PT1027043E (pt) 2005-02-28
AR010346A1 (es) 2000-06-07
PL333950A1 (en) 2000-01-31
BR9713690A (pt) 2000-05-02
CA2274183C (en) 2006-10-24
PL190499B1 (pl) 2005-12-30
ZA9711051B (en) 1999-06-09
NO992804D0 (no) 1999-06-09
WO1998025606A1 (en) 1998-06-18
CZ199199A3 (cs) 1999-09-15
ES2230626T3 (es) 2005-05-01
JP4290765B2 (ja) 2009-07-08
HUP0000695A2 (hu) 2001-05-28
KR20000069396A (ko) 2000-11-25
HK1029947A1 (en) 2001-04-20
CY2501B1 (en) 2005-09-02
KR100499106B1 (ko) 2005-07-01
DE69731562T2 (de) 2005-11-24
HUP0000695A3 (en) 2002-09-30
IL129999A (en) 2004-06-20
CA2274183A1 (en) 1998-06-18
IL129999A0 (en) 2000-02-29
US5856529A (en) 1999-01-05
AU719994B2 (en) 2000-05-18
US6060506A (en) 2000-05-09
US5981571A (en) 1999-11-09
TW476758B (en) 2002-02-21
EP1027043B1 (en) 2004-11-10
DE69731562D1 (de) 2004-12-16
JP2001505916A (ja) 2001-05-08
NO321450B1 (no) 2006-05-15
CZ297673B6 (cs) 2007-02-28
CN1152679C (zh) 2004-06-09
EP1027043A4 (en) 2002-02-20
RU2190609C2 (ru) 2002-10-10
AU5598598A (en) 1998-07-03
NZ335910A (en) 2000-11-24
EP1027043A1 (en) 2000-08-16
HU226524B1 (en) 2009-03-30
DK1027043T3 (da) 2005-01-10
ATE281833T1 (de) 2004-11-15
CN1239886A (zh) 1999-12-29

Similar Documents

Publication Publication Date Title
BR9713690B1 (pt) agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano.
ID29609A (id) Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
NO2005009I2 (no) Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid
ID28219A (id) Turunan 2-(purin-9-il) -tetrahidrofuran-3,4-diol
NO2007004I1 (no) Mycofenolsyre = (E)-6-(1,3-dihydro-4-hydroksy-6-metoksy-7-metyl-3-oksajsobenzofuran-5-yl)-4-, metylheks-4-ensyre
ES1028851Y (es) Juego de construccion.
ZA9811081B (en) (Benzodioxan, Benzofuran or Benzopyran) Derivatives having fundic relaxation properties.
FI971262L (fi) Tehostajat, kuten asetosyringoni
BR9704503A (pt) Tris-aril-s-triazinas substituídas por grupos bifenilila
DK1437359T3 (da) Hidtil ukendte 3,6-hemiketaler fra 9a-azalidklassen
ATE203528T1 (de) Antineurodegenerativ wirksame 10-aminoaliphatyl- dibenz- b,f oxepine
YU10499A (sh) Supstituisani 1,2,3,4-tetrahidro-2-dibenzofuranamini i 2-aminociklohepta /b/benzofurani
ITTO960041A0 (it) Macchina semovente per la stabilizzazione, mediante martellinatura e compattazione, di binari posati su massicciata.
ES1042380Y (es) Palo de hockey productor de sonidos.
DE69737265D1 (de) Herstellung nickelenthaltenden, gesinterten, verfestigten, feritischen rostfreien stahls
DE50007501D1 (de) Benzofuranderivate
NL1008938A1 (nl) Scan-verschervingswerkwijze.
NO973624D0 (no) Vasokonstriktive substituerte 2,3-dihydro-1,4-dioksinopiperidiner
ITGE920060A1 (it) Soluzione sclerosante, ad elevata efficacia, che non produce lesioni iatrogene e procedimento per ottenere tale soluzione.
DK0814804T3 (da) Substituerede benzopyraner
FI960909A0 (fi) Bentsotiofeeniyhdisteet, välituotteet, koostumukset ja menetelmät
ES1033923Y (es) Puya para vara de picadores.
ITTV940032A0 (it) Struttura perfezionata di attrezzatura ginnica particolarmente per la rieducazione fisica.
ES1032162Y (es) Raqueta.
ES1034704Y (es) Juego de composicion.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15Z Prolongation of time limit refused

Free format text: NEGADA A SOLICITACAO DE DEVOLUCAO DE PRAZO UMA VEZ QUE NAO FICOU COMPROVADA A JUSTA CAUSA CONFORMEDEFINIDA NO ART. 221 DA LPI. A COPIA DO PARECER (DAS RAZOES) PODERA SER SOLICITADA ATRAVES DO FORMULARIO 1.05. (DESTA DATA CORRE O PRAZO DE 60 (SESSENTA) DIAS PARA EVENTUAL RECURSO DO INTERESSADO).

B12F Other appeals [chapter 12.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 11.08.2019